Repros Therapeutics
RPRX
RPRX was delisted on the 31st of January, 2018.
56 hedge funds and large institutions have $12.3M invested in Repros Therapeutics in 2015 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 13 increasing their positions, 16 reducing their positions, and 18 closing their positions.
65% more call options, than puts
Call options by funds: $564K | Put options by funds: $342K
3% less funds holding
Funds holding: 58 → 56 (-2)
15.72% less ownership
Funds ownership: 57.38% → 41.67% (-16%)
19% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 16
28% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 18
88% less capital inflows, than outflows
Capital inflows: $4.13M | Capital outflows: $34.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.17M |
| 2 |
ARTA
A.R.T. Advisors
New York
|
+$524K |
| 3 |
D.E. Shaw & Co
New York
|
+$513K |
| 4 |
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
+$441K |
| 5 |
Virtu KCG Holdings
New York
|
+$260K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$14.5M |
| 2 |
Destrier Capital Management
New York
|
-$2.44M |
| 3 |
Morgan Stanley
New York
|
-$2.23M |
| 4 |
Highland Capital Management (Texas)
Dallas,
Texas
|
-$1.84M |
| 5 |
RTW Investments
New York
|
-$1.73M |
RPRX Hedge Fund Activity: Q4 2015 in Review
56 of the 3,823 institutional investors tracked by Wall St. Rank reported a position in Repros Therapeutics (RPRX) for Q4 2015, worth a combined $12.3M — down 88% from $104M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of RPRX and 13 opened new positions — a net loss of 5 holders — while 16 trimmed existing stakes and 13 added.
The largest buyer was Millennium Management, adding an estimated $1.17M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $14.5M sold.
- 56 institutional investors held Repros Therapeutics (RPRX) as of Q4 2015, down from 58 in Q3 2015.
- Funds reported $12.3M of Repros Therapeutics stock for Q4 2015, down 88% quarter-over-quarter.
- 13 funds opened new Repros Therapeutics positions in Q4 2015 and 18 closed out, a net change of -5 holders.
- The largest Repros Therapeutics buyer in Q4 2015 was Millennium Management, an estimated $1.17M added.
- The largest Repros Therapeutics seller in Q4 2015 was Baker Bros. Advisors, an estimated $14.5M sold.
Based on aggregated 13F filings for Q4 2015.